A two-day event packed with leading speakers, research and cutting-edge presentations on the latest advancements in the discovery & development of cancer immunotherapies.
When: April 25th, at 14:10
Where: Immuno UK 2024
Presentation title: “PD-1/PD-L1 Functional Engagement Quantified By QF-Pro® In NSCLC Is A Strong Predictor Of Immune Checkpoint Inhibitors Response”
Presentation Summary: Using Hawk’s QF-Pro® technology to measure PD 1/PD L1 interaction in NSCLC tumour samples of a validation cohort of 188 patients, we very precisely predicted patients’ response to immune checkpoint inhibitors treatment. These results beat the current gold standard biomarker PD-L1 TPS who failed to stratify these patients. QF-Pro® offers the most powerful tool to identify the subset of patients with high expression of PD-L1 TPS that are resistant to treatment and, more strikingly, also PD-L1 TPS
Join Veronique Calleja, PhD, CSO at Hawk Biosystems, on April 25th at 14:10 for an insightful presentation at Immuno UK 2024. She will delve into the topic of “PD-1/PD-L1 Functional Engagement Quantified By QF-Pro® In NSCLC Is A Strong Predictor Of Immune Checkpoint Inhibitors Response,” as part of Track 2: Biomarkers, Precision Medicine & Multi-omics in Immunooncology.
Our solutions allow unveiling protein functions in patient tissue to advanced personalised medicines at an unprecedented resolution.
Want to find out more about our solution and how it could innovate your research? Get in touch and secure a meeting with the team
This project has been co-funded by the European Union’s Horizon Europe research and innovation programme under grant agreement Nº101161495.
“Co-funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them.”
Stay connected
Subscribe to the HAWK Biosystems newsletter and don’t miss any news about our company, our products, events and much more.